Loading people...
Jack Schoenfeld is an Analyst at Time BioVentures, an early-stage venture capital firm based in Southern California. Working alongside firm co-founders D.A. Wallach and Tim Wright, as well as Senior Associate Ryan Moriarty, he evaluates prospective investment opportunities across the life sciences, biotechnology, and healthcare technology sectors. The investment team specifically targets early-stage therapeutics, medical diagnostics, and digital health startups, supporting a broader portfolio where select companies have successfully reached valuations exceeding the $1 billion mark. Prior to transitioning into the venture capital industry, Schoenfeld gained valuable operational experience serving as the Head of Product and Growth at FORE Enterprise. In his current capacity, he leverages this prior product background to analyze early-stage business models and technical milestones, actively identifying emerging medical innovations and biotechnology platforms that address critical healthcare challenges in the clinical market.
Jack Schoenfeld is a key Analyst at Time BioVentures, a prominent venture capital firm specializing in the dynamic and rapidly evolving field of life sciences. In his capacity, Jack plays a crucial role in the firm's investment process, contributing to the rigorous research, due diligence, and analysis of potential investment opportunities. His work is instrumental in identifying innovative startups and technologies that align with Time BioVentures' strategic focus on transformative advancements in biotechnology, pharmaceuticals, and healthcare.
Time BioVentures is known for its commitment to fostering innovation that addresses critical unmet medical needs and improves patient outcomes. Jack's responsibilities involve deep dives into scientific data, market trends, and competitive landscapes to assess the viability and potential impact of emerging life science companies. This includes evaluating novel drug discovery platforms, advanced therapeutic modalities, medical devices, diagnostics, and digital health solutions. His analytical skills are vital in helping the firm make informed decisions about where to deploy capital to generate both financial returns and significant societal benefit.
While specific details of Jack Schoenfeld's individual career background are not extensively publicized, his role as an Analyst at Time BioVentures suggests a strong foundation in either scientific research, finance, or a combination thereof, tailored to the complexities of the biotech investment landscape. Professionals in such positions typically possess a keen understanding of scientific principles, regulatory pathways, and market dynamics unique to the healthcare and life sciences industries. Their expertise is essential for navigating the high-risk, high-reward nature of early-stage biotech investing.
Regarding notable investments, Time BioVentures, as a firm, actively seeks out companies that are at the forefront of scientific discovery and technological innovation. While individual investment contributions by Jack Schoenfeld are part of the firm's collective effort and not typically attributed publicly to specific analysts, the firm's portfolio generally reflects investments in areas such as gene therapy, precision medicine, oncology, neuroscience, and infectious disease. Jack's analytical contributions help shape the firm's overall investment strategy and portfolio composition, aiming to back ventures that promise to redefine healthcare paradigms. His dedication to uncovering and supporting cutting-edge science underscores Time BioVentures' mission to be a catalyst for progress in the bio-economy.
Jack Schoenfeld is an Analyst at Time BioVentures, a venture capital firm focused on investments in the life sciences sector.
As an Analyst at Time BioVentures, Jack Schoenfeld contributes to investments in early-stage biotechnology, pharmaceuticals, medical devices, and other life sciences innovations aimed at improving human health.
Jack Schoenfeld works as an Analyst at Time BioVentures, a venture capital firm specializing in life sciences investments.
